bcnu

Phase 2Small molecule

GGeneral Oncology, Inc.

bcnu is one of 63 small molecule programs targeting Pediatric Brain Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pediatric Brain TumorTerminated

Metastatic Uveal MelanomaRecruiting

Metastatic CancerRecruiting

LymphomaCompleted

Pediatric Brain TumorPreclinical

Terminated

Metastatic Uveal MelanomaPreclinical

Recruiting

Metastatic CancerPhase 1

Recruiting

LymphomaPhase 2

Completed

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

bcnu

GGeneral Oncology, Inc.

Phase 2

7 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Lymphoma

NCT03125642

Q4 2028

Phase 1Recruiting

Metastatic Cancer

NCT04150042

Q3 2032

PreclinicalRecruiting

Metastatic Uveal Melanoma

NCT06626516

Clinical

Trials by Indication[1]

Lymphoma7 trials

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00505921·27 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005613·147 enrolled

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Terminated·SStanford University·Phase 2·NCT00481832·50 enrolled

Show 4 more trials

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Completed·—·N/A·NCT01702961·75 enrolled

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01538472·40 enrolled

Auto Stem Cell Transplant for Lymphoma Patients

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03125642·150 enrolled

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT01011920·227 enrolled

Diffuse Large B-Cell Lymphoma2 trials

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Completed·LLymphoma Study Association·Phase 3·NCT00137995·481 enrolled

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00499018·399 enrolled

Efficacy1 trial

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209222·360 enrolled

Multiple Myeloma1 trial

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

HIV1 trial

Autologous Transplant in HIV Patients (BMT CTN 0803)

Completed·MMedical College of Wisconsin·Phase 2·NCT01141712·43 enrolled

6 more indications

Lymphoid Malignancies1 trial

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00536978·22 enrolled

Pediatric Brain Tumor1 trial

Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis

Terminated·WWashington University School of Medicine·N/A·NCT03591861·2 enrolled

Hematologic Malignancies1 trial

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Completed·SSally Arai·Phase 1·NCT00477035·22 enrolled

Metastatic Cancer1 trial

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Recruiting·GGeneral Oncology, Inc.·Phase 1·NCT04150042·24 enrolled

Prophylaxis1 trial

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Completed·SStanford University·Phase 2·NCT00350181·11 enrolled

Metastatic Uveal Melanoma1 trial

A Phase I/II Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma

Recruiting·TThomas Jefferson University·Preclinical·NCT06626516·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for bcnu. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bcnu compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bcnu. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — General Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGeneral Oncology, Inc.

bcnu

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Q3 2032

Trials by Indication[1]

Lymphoma7 trials

Diffuse Large B-Cell Lymphoma2 trials

Efficacy1 trial

Multiple Myeloma1 trial

HIV1 trial

Lymphoid Malignancies1 trial

Pediatric Brain Tumor1 trial

Hematologic Malignancies1 trial

Metastatic Cancer1 trial

Prophylaxis1 trial

Metastatic Uveal Melanoma1 trial

References

Drug Info

Quick Facts

Related News